Cancer Clinical Trial
Official title:
Promotora-based Latino Family CVD Risk Reduction: Remaking the Home Environment
Verified date | September 2023 |
Source | University of California, Los Angeles |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This family environment-focused health behavior change intervention is being carried out by extensively trained community health workers (promotores) familiar with the community in East Los Angeles. The hypothesis being tested is that home environment-focused health behavior change will reduce risk of arterial stiffness, an early-in-life predictor of heart disease. The community health workers will provide most of the health promotion counseling. The promotores will provide up to 16 counseling sessions to a designated adult family member without diabetes. The sessions will focus on improving the home environment in order to reduce television viewing, increase fruit and vegetable intake, decrease intake of refined carbohydrates, prompt more frequent monitoring of body weight and increase daily physical activity. The lifestyle change goals will be tailored to the families' capacity for change and will be consistent with the Dietary Guidelines for Americans, especially the MyPlate.gov messages, the Dietary Approaches to Stop Hypertension (DASH) diet and at least 30 minutes of daily moderate physical activity.
Status | Completed |
Enrollment | 204 |
Est. completion date | October 2014 |
Est. primary completion date | October 2014 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Resides in East Los Angeles - Home includes family member (spouse or 1st degree relative)who has been diagnosed with type 2 diabetes Exclusion Criteria: - BMI>40; - Any condition that prevents engaging in daily physical activity / walking; - pregnant; - breast feeding; - cardiovascular (CVD) event within 12 months; - cancer requiring chemotherapy; - other medical condition requiring active lifestyle intervention/dialysis; - severe CVD or other disease known to significantly limit life expectancy. |
Country | Name | City | State |
---|---|---|---|
United States | Roybal Comprehensive Health Center | Los Angeles | California |
Lead Sponsor | Collaborator |
---|---|
University of California, Los Angeles | National Heart, Lung, and Blood Institute (NHLBI), University of Southern California |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in arterial stiffness as measured by pulse wave velocity | Pulse wave velocity is a measure of arterial stiffness that is sensitive to changes in health-related lifestyle changes. | baseline, 6, 12, 24 months follow-up | |
Primary | Change in arterial stiffness as measured by the Augmentation index | Augmentation index is another measure of arterial stiffness, also sensitive to changes in health-related lifestyle behaviors. | baseline, 6, 12 and 24 months follow-up | |
Secondary | Change in fasting glucose | Fasting blood glucose | baseline, 6, 12, 24 months | |
Secondary | Changes in glycosylated hemoglobin A1c (HbA1c) | Glycosylated hemoglobin A1c. Measure of glucose control over several months. | baseline, 6, 12, 24 months follow-up | |
Secondary | Changes in answers to MyPlate evaluation questions | Self-report questions about adherence to MyPlate.gov recommendations. These include questions about daily fruit intake, vegetable intake, replacement of sugary beverages with water, effort to make at least 1/2 of grain intake whole grain, effort to seek out lower sodium options, and daily intake of non-fat or low-fat milk. | baseline, 6, 12, 24 months follow-up | |
Secondary | Changes in food frequency measure of fruit and vegetable intake | Block Food Frequency assessment conducted in Spanish by interview. Information will include estimate of total fruit and vegetable intake over the last 6 months. | Baseline, 6, 12, 24 months follow-up | |
Secondary | Changes in waist circumference | Measure of waist circumference, a common predictor of cardiovascular risk | baseline, 6, 12 and 24 months | |
Secondary | Change in aerobic capacity | Bruce protocol treadmill test. Estimate the VO2max (maximum aerobic capacity) using Foster's equation. | Baseline, 6, 12, 24 months | |
Secondary | Change in metabolic syndrome score | Metabolic syndrome marker levels. The ATP III criteria for metabolic syndrome markers include:
sex-specific excess waist circumference (men > 102 cm, women >88 cm), fasting plasma triglycerides >= 120 mg/dl, fasting plasma HDL(men)<40 or (women)<50 mg/dl, blood pressure >=135/85, fasting glucose >=110 mg/dl). Each subject's metabolic syndrome marker level can range between zero and five, with zero representing no metabolic syndrome risk and five representing maximum risk. The a priori expectation is that each marker will be treated as equally important but this study will provide the opportunity to examine this assumption critically. |
Baseline, 6, 12, 24 months | |
Secondary | Change in plasma lipids | Plasma lipids to be measured include LDL-cholesterol, HDL-cholesterol and triglycerides. Blood samples will be obtained by venipuncture. | Baseline, 6, 12, 24 months | |
Secondary | Change in blood pressure | Blood pressure will be assessed in study participants sitting quietly by trained personnel using regularly calibrated sphygmomanometry. | Baseline, 6, 12, 24 months | |
Secondary | Change in physical activity assessment | International Physical Activity Questionnaire - short form (IPAQ-short). Questions ask about the number of days in the last 7 days that the participant exercised vigorously or moderately vigorously. Follow-up questions query the participant about the time (minutes & hours) spent per day in doing vigorous or moderately vigorous physical activity on those days when they exercised. | Baseline, 6, 12, 24 months | |
Secondary | Change in body mass index (BMI) | Body mass index (BMI) obtained by taking the ratio of measured weight (kg) to measured height (m). Weight is obtained using a regularly calibrated balance beam scale. Height is obtained using a stationary stadiometer. | Baseline, 6, 12, 24 months | |
Secondary | Change in quality of life | The SF-12 is a well-accepted short form of the well-known SF-36 quality of life instrument. | Baseline, 6, 12, 24 | |
Secondary | Change in weight loss strategies | Questionnaire includes 11 items that query the participant about weight control strategies used in the last year, including: exercise, restricting calories, fasting, diet pills, vomiting / laxative use, joining a gym, joining a commercial weight loss program such as WeightWatchers, meal replacement products, herbal medicines, diet bars, restriction on TV watching. | Baseline, 6, 12, 24 | |
Secondary | Change in endothelial function | Flow-mediated dilation is the most widely used non-invasive test for assessing endothelial function, that is, the functional status of the inner lining of the major blood vessels. This technique measures endothelial function by inducing reactive hyperemia (blood volume expansion) via temporary arterial occlusion (blocking blood flow with inflated blood pressure cuff) and measuring the resultant relative increase in blood vessel diameter via ultrasound. | Baseline, 6, 12, 24 months | |
Secondary | Change in self-efficacy to adhere to DASH-style dietary pattern | List of 10 self-efficacy items that assess the study participant's confidence that she/he can adhere to various features of the Dietary Approaches to Stop Hypertension (DASH) diet. | Baseline, 6, 12, 24 months | |
Secondary | Change in mental health status | Mental health index-5 (MHI-5) consists of 5 questionnaire items designed to assess emotional well-being. | Baseline, 6, 12, 24 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|